Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- COPD
- Interventions
- Drug: short acting β2- agonist
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 568
- Registration Number
- NCT00557466
- Locations
- 🇬🇧
Novartis Investigator Site, Whitstable, United Kingdom
🇵🇱Novartis Investigator site, Mrozy, Poland
🇩🇪Novartis Investigator Site - 2 sites, Bonn, Germany
Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma
- Conditions
- Asthma
- Interventions
- Drug: placebo to indacaterol/mometasone
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 37
- Registration Number
- NCT00557440
- Locations
- 🇩🇪
Novartis Investigator Site, Rostock, Germany
🇧🇪Novartis Investigator site, Ghent, Belgium
Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2012-11-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 257
- Registration Number
- NCT00558285
- Locations
- 🇹🇷
Novartis Investigator Site, Izmir, Turkey
🇫🇷Novartis investigator site, Martigues, France
🇮🇹Novartis Investigator site, Modena, Italy
Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma
- Conditions
- Asthma
- Interventions
- Drug: placebo to indacaterol maleate/mometasone furoate
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 31
- Registration Number
- NCT00556673
- Locations
- 🇩🇪
Novartis Investigator Site, Berlin, Germany
Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 115
- Registration Number
- NCT00554606
- Locations
- 🇹🇷
Novartis Investigator Site, Sihhiye/Ankara, Turkey
Evaluation of HIV-1, HCV and HBV Blood Screening Tests With Human Blood Donor Specimens
- Conditions
- Screening for the Presence of HIV-1, RNA and HBV DNA in Blood Donations
- Interventions
- Device: Blood test
- First Posted Date
- 2007-11-01
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 10290
- Registration Number
- NCT00552214
- Locations
- 🇨🇳
Taipei Blood Center Taiwan Blood Service Foundation (TBSF), Taipei, Taiwan
Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2011-03-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 142
- Registration Number
- NCT00549601
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Spain
To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 509
- Registration Number
- NCT00550095
- Locations
- 🇪🇬
Novartis Investigative Site ,, Cairo, Egypt
Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: Valsartan/amlodipineDrug: Valsartan/hydrochlorothiazide (HCTZ)Drug: Amlodipine/hydrochlorothiazide(HCTZ)Drug: Valsartan/amlodipine/hydrochlorothiazide(HCTZ)
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2010-09-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 111
- Registration Number
- NCT00548067
- Locations
- 🇮🇳
Novartis investigative site, Mehasana, India
🇮🇳Novartis Investigative site, Mangalore, India
🇮🇳Novartis Investigative Site, Ahmedabad, India
Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma
- First Posted Date
- 2007-10-18
- Last Posted Date
- 2010-09-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00546143
- Locations
- 🇩🇪
Novartis Investigative Site, Berlin, Germany
🇿🇦Novartis Investigative site, Bloemfontein, South Africa
🇩🇪Novartis investigative site, Mainz, Germany